Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.

Dadheech S, Rao AV, Shaheen U, Hussien MD, Jain S, Jyothy A, Munshi A.

Gene. 2013 Dec 1;531(2):301-5. doi: 10.1016/j.gene.2013.08.078. Epub 2013 Sep 11.

PMID:
24036429
2.

Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.

Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.

N Engl J Med. 1998 Aug 13;339(7):417-23.

3.

Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major.

Hagag AA, Elfaragy MS, Elrifaey SM, Abd El-Lateef AE.

Infect Disord Drug Targets. 2015;15(3):189-95.

PMID:
26239735
4.

UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.

Limenta LM, Jirasomprasert T, Tankanitlert J, Svasti S, Wilairat P, Chantharaksri U, Fucharoen S, Morales NP.

Br J Clin Pharmacol. 2008 Jun;65(6):908-16. doi: 10.1111/j.1365-2125.2008.03103.x. Epub 2008 Mar 3.

5.
6.
7.

A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.

Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.

Hemoglobin. 2006;30(2):263-74.

PMID:
16798652
8.
9.

Iron chelation with oral deferiprone in patients with thalassemia.

Wonke B, Telfer P, Hoffbrand AV.

N Engl J Med. 1998 Dec 3;339(23):1712; author reply 1713-4. No abstract available.

PMID:
9867540
10.

An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major.

Diav-Citrin O, Atanackovic G, Koren G.

Ther Drug Monit. 1999 Feb;21(1):74-81. Erratum in: Ther Drug Monit. 2004 Apr;26(2):following table of contents.

PMID:
10051057
11.
12.

Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.

Viprakasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, Srichairatanakool S, Pooliam J, Supajitkasem S, Suriyaphol P, Tanphaichitr VS, Tuchinda S.

Am J Hematol. 2013 Apr;88(4):251-60. doi: 10.1002/ajh.23386. Epub 2013 Mar 5.

13.

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.

Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.

Circulation. 2007 Apr 10;115(14):1876-84. Epub 2007 Mar 19.

14.

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.

Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, D'Ascola DG, Rizzo A, Midiri M.

Blood Cells Mol Dis. 2002 Mar-Apr;28(2):196-208.

PMID:
12064916
15.

Deferiprone: new preparation. Poorly assessed.

[No authors listed]

Prescrire Int. 2000 Oct;9(49):131-5.

PMID:
11603411
16.

Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.

El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.

Ann Hematol. 2008 Jul;87(7):545-50. doi: 10.1007/s00277-008-0471-2. Epub 2008 Mar 20.

PMID:
18351337
17.

Deferiprone chelation therapy for thalassemia major.

Galanello R, Campus S.

Acta Haematol. 2009;122(2-3):155-64. doi: 10.1159/000243800. Epub 2009 Nov 10.

PMID:
19907153
18.

Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.

Ayyub M, Ali W, Anwar M, Waqar A, Khan MN, Ijaz A, Hussain T, Hussain S.

J Ayub Med Coll Abbottabad. 2005 Oct-Dec;17(4):12-5.

PMID:
16599026
19.

Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.

Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.

Hemoglobin. 2011;35(3):206-16. doi: 10.3109/03630269.2011.570674.

PMID:
21599433
20.

Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.

Marshall R, Tricta F, Galanello R, Leoni G, Kirkland D, Minto S, Spino M.

Mutagenesis. 2003 Sep;18(5):457-63.

PMID:
12960415

Supplemental Content

Support Center